The news of Canaccord Genuity maintaining a Buy rating on Vicarious Surgical is positive for the stock. However, the lowering of the price target from $12 to $9 may create some uncertainty among investors, potentially offsetting the positive sentiment. As a result, the short-term impact on the stock price is expected to be neutral.